As SOX2 was assumed to be a significant marker to evaluate the progression of prostate cancer (29), the treatment with metabolites from Halobacteriumsalinarum IBRC M10715 could prevent the progression of human prostate cancer. Here, SOX2 is linked to prostate cancer.